Trial Profile
A phase I study of oral respiratory syncytial virus vaccine (Vaxart)
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 30 Jun 2016
Price :
$35
*
At a glance
- Drugs Respiratory syncytial virus vaccine-Vaxart (Primary)
- Indications Respiratory syncytial virus infections
- Focus Adverse reactions
- 28 Jun 2016 Status changed from planning to recruiting, as reported in a Vaxart media release.
- 25 Nov 2015 New trial record
- 19 Nov 2015 According to a Vaxart media release, the company expects to initiate this trial in 2016.